VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3] (NCT06264180)
Randomized, Ph3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination With Nivolumab Vs Treatment of Physician's Choice in Patients With Advanced Melanoma That Progressed on Anti-PD-1 and Anti-CTLA-4 Containing Treatment [IGNYTE-3]
🩺 Plain-English Summary (8th-Grade Level)
This is a randomized, controlled, multicenter, open-label Phase 3 clinical study comparing VO in combination with nivolumab versus Physician's Choice treatment for patients with unresectable Stage IIIb-IV cutaneous melanoma whose disease progressed on an anti PD-1 and an anti-CTLA-4 containing regimen (administered either as a combination regimen or in sequence) or who are not candidates for treatment with an anti-CTLA-4 therapy.
Who can join: Review the eligibility criteria below.
Location: Banner MD Anderson Cancer Center — Gilbert, Arizona
Age range: 12 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (81 Sites)
Showing the first 25 of 81 sites.
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- UC San Diego Moores Cancer Center — La Jolla, California
- The Angeles Clinic and Research Institute — Los Angeles, California
- USC Norris Comprehensive Cancer Center — Los Angeles, California
- UCLA Department of Medicine - Hematology/Oncology — Los Angeles, California
- UC Irvine Health, Chao Family Comprehensive Cancer Center — Orange, California
- Stanford Cancer Institute — Palo Alto, California
- Sutter Medical Group — Sacramento, California
- San Francisco Oncology Associates — San Francisco, California
- UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California
- University of Colorado Hospital - Anschutz Cancer Pavilion — Aurora, Colorado
- The Melanoma and Skin Cancer Institute — Englewood, Colorado
- MedStar Washington Hospital Center — Washington D.C., District of Columbia
- Memorial Cancer Institute at Memorial Regional Hospital — Hollywood, Florida
- Baptist MD Anderson Cancer Center — Jacksonville, Florida
- Moffitt Cancer Center — Tampa, Florida
- Winship Cancer Institute, Emory University — Atlanta, Georgia
- Northwestern Memorial Hospital — Chicago, Illinois
- Advocate Lutheran General Hospital — Park Ridge, Illinois
- University of Iowa — Iowa City, Iowa
- University of Kansas Cancer Center — Westwood, Kansas
- University of Louisville Brown Cancer Center — Louisville, Kentucky
- Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion) — Detroit, Michigan
- Corewell Health — Grand Rapids, Michigan
- University of Minnesota — Minneapolis, Minnesota
📞 Contact the Study Coordinator
Phone: (781) 222-9570
Email: clinicaltrials@replimune.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Melanoma
- Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial — Fairhope, Alabama
- Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery — Birmingham, Alabama
- Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma — Mobile, Alabama
- A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma — Scottsdale, Arizona
- A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma — Pittsburgh, Pennsylvania
- Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors — St Louis, Missouri
Explore by condition: All Advanced Melanoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.